Ibandronsäure Actavis

Ibandronic acid, the active ingredient in Ibandronsäure Actavis, is a bisphosphonate presented as an intravenous injection solution for intravenous use. It treats postmenopausal osteoporosis and Paget's disease of bone in adults and belongs to the bone‑resorption inhibitor class, administered by healthcare professionals in a clinical setting.

GNH USA supplies Ibandronsäure Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibandronic acid is a bisphosphonate that reduces excessive bone turnover in conditions characterized by increased osteoclast activity.

- Postmenopausal osteoporosis: improves bone mineral density and lowers the risk of vertebral and non‑vertebral fractures. - Osteoporosis (general): increases bone strength and reduces fracture incidence in patients with low bone mass. - Paget's disease of bone: normalises abnormal bone remodeling and alleviates associated pain and deformities.

Ibandronic acid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Acute‑phase reaction (fever, chills, rigors) - Musculoskeletal pain (myalgia, arthralgia) - Nausea or vomiting - Headache

Serious or Rare Side Effects: - Osteonecrosis of the jaw - Atypical femur fracture - Severe renal impairment

Before using Ibandronsäure Actavis, several safety considerations should be observed.

- Renal function: assess baseline creatinine clearance and avoid use in severe renal impairment. - Calcium/Vitamin D status: correct deficiencies prior to infusion to reduce hypocalcaemia risk. - Hypocalcemia risk: monitor serum calcium levels during treatment. - Pregnancy and lactation: avoid unless the potential benefit justifies the potential risk. - Concomitant bisphosphonates: do not administer duplicate therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ibandronic acid can interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Concurrent use with other bisphosphonates. - Co‑administration with nephrotoxic agents (e.g., aminoglycosides, NSAIDs). - Calcium or multivitamin supplements given within 4 hours of the infusion.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin may increase bleeding tendency. - Systemic corticosteroids can heighten the risk of hypocalcaemia. - Oral contraceptives may influence calcium metabolism and require monitoring.